Shanghai BDgene’s BD111 Gene Therapy Advances to Phase II Clinical Trials

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has advanced its BD111 pipeline candidate into Phase II clinical trials. The study is a multi-center, randomized, single-dosage trial designed to assess the safety, tolerability, and efficacy of BD111 in treating type I herpes simplex virus (HSV-1) stromal keratitis.

BD111 Mechanism and Innovation
BD111 utilizes BDgene’s proprietary VLP delivery technology to transduce CRISPR, directly targeting and cutting the HSV-1 genome. This approach aims to eliminate the HSV-1 virus genome and treat herpes virus keratitis. BD111 is the first in vivo gene editing drug in China to enter Phase I and II clinical trials. Globally, it is the second in vivo gene editing therapy to reach Phase II clinical trials, following Intellia’s in vivo gene editing therapy pipeline in the United States.-Fineline Info & Tech